Developer docs
API playgroundTry for free, no card

Search company profiles

SRI International

Full company profile

uuid000325x

Namestring
SRI International
Legal namestring
SRI International
Websiteurl
sri.com
Company typeenum
Private
Founded yearint
1946
Descriptiontext

SRI International is an independent, nonprofit research institute founded in 1946 and headquartered at 333 Ravenswood Avenue, Menlo Park, California, with additional Silicon Valley, Princeton (Sarnoff Corporation), San Diego, other U.S. sites, and a Tokyo office. The institute operates five research divisions — Advanced Technology & Systems, Biosciences, Education, Information & Computing Sciences, and Integrated Systems & Solutions — and runs an explicit Commercialization arm comprising Commercial R&D, Ventures, the Center for Innovation Strategy & Policy, and the Nomura-SRI Innovation Center. Its workforce of 1,001–5,000 serves U.S. federal agencies (DARPA, ARPA-H, NASA, NIH, NSF, DOE, IARPA, Army/Marines) and commercial customers across aerospace, pharma, energy, banking, and technology.

SRI's core proprietary technology spans the FOX Three biosensor and molecular-guidance platform (radionuclide therapy and at-home multi-cancer screening via the ARPA-H POSEIDON program, up to $34M awarded in 2025), the BioCyc family of metabolic pathway databases licensed to 11,000+ users, the DASL (Deep Adaptive Semantic Logic) framework for data-efficient AI, the FRASTA 3D fracture-analysis system, the FlexTrain military training instrumentation, the QED-C quantum consortium (270 members), and a deep AI research stack built around the Artificial Intelligence Center (founded 1966), whose outputs include CALO (the progenitor of Siri), RANSAC computer vision, and current agent frameworks (ATHENA, COLLEAGUE). Nine IEEE Milestones and nine Emmy awards attest to a multi-decade innovation record.

SRI's business model rests on multi-year fee-for-service contract R&D with government and industry (e.g., the five-year, $150M DARPA CALO/PAL program), supplemented by licensing of patented inventions and FDA-approved drugs (bexarotene, pralatrexate, vidarabine), subscription licensing of the BioCyc database family, equity realizations from spin-out companies (Siri → Apple, Tempo AI → Salesforce, Summly → Yahoo, Ravenswood Solutions spun out 2024, Autonomique spun out 2026), and consortium management fees (QED-C). Pricing is quote-based and engagement-specific, with no public price list. Distribution is direct enterprise and government sales, augmented by technology licensing to OEMs and the creation of independent spin-out companies that take products to market while SRI retains a partnership stake.

Short descriptiontext

SRI International is an independent nonprofit research institute founded in 1946 and headquartered in Menlo Park, California, conducting multidisciplinary contract R&D for U.S. federal agencies (DARPA, ARPA-H, NASA, NIH, NSF, DOE, IARPA) and commercial customers across biosciences, AI, quantum, security, and space, and commercializing technology through licensing and spin-out companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, government R&D contracts, technology licensing, artificial intelligence research, biopharmaceutical development
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Research and Development Services
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model6 records
1Commercial R&D contracts
TypeProfessional Services
Description

Fee-for-service and contract research performed for commercial customers (e.g., Merrill Lynch cash management accounts, Valeant/Eisai/Ligand pharmaceutical development, Ricoh digital fax). SRI states it collaborates "closely with government and commercial customers to meet their precise needs and specifications."

sri.com
2Government R&D contracts and grants
TypeProfessional Services
Description

Multi-year awards from federal agencies including DARPA (e.g., $150M CALO program, CHERI architecture), ARPA-H (up to $34M for at-home cancer screening), Department of Energy / SETO ($900K in 2017 for PV recycling), NIH, NSF, IARPA, and NASA.

sri.com
3Technology licensing and royalties
TypeLicensing Royalties
Description

Out-licensing of patented inventions and FDA-approved drug royalties. Examples: Ricoh (digital fax Z-60 / RIFAX 600s in 1973), Eisai/Valeant (bexarotene/Targretin for cutaneous T-cell lymphoma, FDA approved 1999), Allos Therapeutics (pralatrexate, FDA approved 2009), Mitsubishi Heavy Industries / Osaka Gas / Chubu Electric (FRASTA), Fourward Technologies (Eyetracker).

sri.com
4Spin-out ventures and equity realizations
TypeTransaction Fee
Description

Creation of independent companies around SRI technology that the institute may retain a partnership stake in (e.g., Siri → Apple acquisition 2010; Tempo AI → Salesforce; Summly → Yahoo; Meta → Chan-Zuckerberg Initiative; Ravenswood Solutions spun out 2024). The Ventures arm manages these equity positions.

sri.com
5Scientific database subscriptions / licensing
TypeSubscription Recurring
Description

Licensing of the BioCyc / MetaCyc / EcoCyc / HumanCyc family of bioinformatics databases and Pathway Tools software to 11,000+ university and corporate users; supported by NIH funding.

sri.com
6Strategic innovation partnerships
TypeManaged Services
Description

Joint ventures and co-development programs such as the Nomura-SRI Innovation Center, and consulting/coordination contracts like the Flinn Foundation Arizona Bioscience Roadmap engagement.

sri.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Quote-based contract R&D engagements, not publicly priced.
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is per-engagement, contract-based, with specific award amounts disclosed in source (e.g., up to $34M from ARPA-H in 2025, $900K from DOE/SETO in 2017). No published price list available.

sri.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1BioCyc
Description

Family of bioinformatics knowledge bases and tools (including MetaCyc, EcoCyc, HumanCyc, and Pathway Tools) developed by SRI's Bioinformatics Research Group; licensed by over 11,000 users to support biological research.

sri.com
+2 more records
Core offering1 text field

SRI International is an independent nonprofit research institute that performs multidisciplinary contract research and development for U.S. government agencies and commercial customers across biosciences, advanced technology and systems, information and computing sciences, and integrated systems and solutions. The institute sells custom R&D services under multi-year contracts and grants, licenses patented inventions and FDA-approved drugs to industry partners, and spins out independent companies to commercialize breakthrough technologies such as Siri, Ravenswood Solutions, and Autonomique.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to $34 million awarded by ARPA-H to develop at-home screening tests capable of detecting 30+ cancer types (2025).
+5 more records
Product overview1 text field

SRI International is a global, independent nonprofit R&D institute (founded 1946) operating as a multi-division research organization rather than a single commercial product. Its Artificial Intelligence Center (founded 1966) anchors a portfolio that includes the FOX Three platform for molecular biosensing and cancer diagnostics, the BioCyc family of bioinformatics databases with Pathway Tools software, and AI agent research products including DASL (Deep Adaptive Semantic Logic), AiCorb generative architecture design, the COLLEAGUE agent framework, and the ATHENA virtual CoP member. Commercialized spinouts and licensed products include Siri (acquired by Apple), Ravenswood Solutions (military training, spun out 2024), Autonomique (teleoperation robotics, spun out 2026), and the FRASTA fracture analysis system. SRI also manages the Quantum Economic Development Consortium (QED-C) and operates the SRI Dish radio antenna for satellite calibrations and spacecraft communications.

Product and service9 records
1FOX Three biosensor and molecular guidance platform
CategoryBiosensor / cancer diagnostics platform
Description

SRI's molecular guidance system platform enabling rapid, tumor-specific radionuclide delivery. Originally developed for neuroendocrine tumors; extended to pancreatic ductal adenocarcinoma, glioblastoma, and at-home multi-cancer screening through the ARPA-H POSEIDON program.

2BioCyc database collection (BioCyc, MetaCyc, EcoCyc, HumanCyc)
CategoryScientific database / bioinformatics knowledge base
Description

Comprehensive Pathway/Genome Databases for thousands of organisms, including EcoCyc (E. coli), MetaCyc (largest curated metabolic knowledge base), HumanCyc, and BioCyc. Licensed by over 11,000 users at universities and corporate labs worldwide; supported by U.S. NIH funding.

3Pathway Tools software
CategoryBioinformatics software
Description

SRI's bioinformatics software suite supporting metabolic pathway queries, genome browsing via the Genome Explorer browser, multi-omics visualization, and the Comparative Genome Dashboard for cross-organism gene-function comparison.

4DASL (Deep Adaptive Semantic Logic)
CategoryAI framework
Description

Next-generation AI technology that combines state-of-the-art machine learning with reasoning mechanisms to learn from limited data combined with human knowledge, identifying problems and explaining them clearly.

5FRASTA (Fracture Surface Topography Analysis)
CategoryMaterials analysis technology
Description

3D fractography system that reconstructs fracture events using confocal optics and scanning laser microscopy to diagnose and predict fatigue failure in pipelines, aircraft, bridges, and power plants. Licensed to NASA and to Japanese companies including Mitsubishi Heavy Industries, Osaka Gas Company, and Chubu Electric Power Company.

6FlexTrain multi-mission instrumentation system
CategoryMilitary training instrumentation system
Description

Live, virtual, and constructive training integration system used by the Army National Guard's eXportable Combat Training Capability (XCTC) program to train combat and functional brigades at home stations. Now operated by the Ravenswood Solutions spinout.

7Quantum Economic Development Consortium (QED-C)
CategoryConsortium management / quantum technology coordination
Description

Public-private partnership established under the National Quantum Initiative Act of 2018 and managed by SRI International. Coordinates 270 members from government agencies, universities, and private sector companies in quantum technology, workforce, standards, and use cases.

8SRI contract R&D services for federal and commercial customers
CategoryContract research and development services
Description

Multidisciplinary contract research and development services delivered to U.S. federal agencies and commercial customers across biosciences, advanced technology and systems, information and computing sciences, and integrated systems and solutions. Engagements are multi-year and tailored to specific customer needs.

9Nomura-SRI Innovation Center
CategoryJoint innovation center / technology transfer
Description

Joint innovation center with Nomura supporting Japanese-market partnerships, joint laboratories, co-development, technology transfer, and talent exchange between Silicon Valley and Japan.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
1Kalekona Radiotheranostics
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

SRI and Kalekona Radiotheranostics announced a strategic partnership to develop peptide receptor radionuclide therapy (PRRT) for pancreatic ductal adenocarcinoma and glioblastoma, utilizing SRI's FOX Three platform. The platform allows rapid, tumor-specific radionuclide delivery, now extended beyond neuroendocrine tumors to include pancreatic and brain tumors.

einpresswire.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-20
Description

ARPA-H selected SRI's multi-party team — including Foothold Labs, Triple Ring Technologies, and Beacon DX Health — under the POSEIDON program to develop an at-home cancer screening test capable of detecting more than 30 cancer types in early stages. The award is for up to $34 million and leverages SRI's FOX Three biosensor/molecular-guidance platform, AI, and machine learning.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

The Flinn Foundation commissioned SRI to deliver an updated Arizona Bioscience Roadmap unveiled in September 2025, highlighting Flagstaff as a leading hub for medical devices, healthcare delivery, precision medicine, and biotechnology.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-19
Description

In September 2024, SRI spun out Ravenswood Solutions as an independent small business focused on fielding scalable, modular solutions for training, testing, and operations across defense and commercial applications. SRI "remains a valuable business partner" to Ravenswood, providing innovative technologies and technical expertise; Ravenswood is headquartered in Fremont, California.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

QED-C is a public-private partnership established under the National Quantum Initiative Act of 2018 and managed by SRI International; 270 members from government agencies, universities, and private sector. SRI coordinates investment in quantum technology, workforce, standards, and use cases.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2003-01-01
Description

Long-term R&D partnership including the five-year, $150M PAL program (CALO cognitive assistant, 22 institutions, 300+ researchers) and ongoing DARPA-funded programs such as CHERI capability-based hardware architecture and Artificial Social Intelligence for Successful Teams (ASIST). Newton's 41-year RISKS Digest was also based at SRI.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2002-01-01
Description

"Pralatrexate was ultimately identified as a viable clinical candidate and was licensed to Allos Therapeutics for further development in 2002." FDA-approved 2009 for peripheral T-cell lymphoma.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on1999-01-01
Description

"Bexarotene (trade name Targretin) was developed by the San Diego biotech company, Ligand, which subsequently licensed worldwide rights to a Japanese pharmaceutical company, Eisai, in 1999. It is now marketed in the U.S. by the Canadian pharmaceutical company, Valeant, which acquired rights to the drug from Eisai in 2013."

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on1988-01-01
Description

"In 1988, the technology [Eyetracker] was licensed to Fourward Technologies, which continued its development and marketing and installed Eyetrackers all over the world." Developed at SRI under NASA contract from 1965-1988.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on1973-04-01
Description

"In 1970, SRI International was contracted by Savin, CBS Television Services and Dacom to commercialize… digital fax. SRI developed the Z-60 prototype. In 1973, Ricoh acquired the rights to the technology; they formed a subsidiary, Rapifax Corporation, to market and distribute the new machine." Ricoh launched the RIFAX 600s, the world's first commercially available digital fax machine.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on1969-10-29
Description

Historical consortium that built ARPANET and the first Internet connection. "The very first transmission on the ARPANET occurred at 10:30 p.m. on October 29, 1969, when UCLA attempted to send a message to SRI." Subsequent SRI contributions include internetworking (1977) and the Network Information Center (NIC, 1970-1991).

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

SRI's CALO project spun out as Siri in 2007; Apple acquired Siri and integrated it into the iPhone 4S in 2011, bringing voice assistants into the mainstream. SRI remains an originator-licensor relationship.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

SRI spin-off Tempo AI was acquired by Salesforce, extending SRI's commercialization lineage.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

SRI spin-offs Summly was acquired by Yahoo; Meta was acquired by the Chan-Zuckerberg Initiative.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensees of SRI's FRASTA fracture-analysis technology for diagnosing and predicting fatigue failure in pipelines, aircraft, bridges, and power plants. NASA and three Japanese companies use FRASTA to analyze 3D fracture surface topography.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

SRI operates the Nomura-SRI Innovation Center as part of its Commercialization division (sri.com/commercialization/the-nomura-sri-innovation-center/), supporting Japanese-market partnerships, joint labs, and technology transfer.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability16 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SRI International

Research and Development Servicessri.com

SRI International is an independent nonprofit research institute founded in 1946 and headquartered in Menlo Park, California, conducting multidisciplinary contract R&D for U.S. federal agencies (DARPA, ARPA-H, NASA, NIH, NSF, DOE, IARPA) and commercial customers across biosciences, AI, quantum, security, and space, and commercializing technology through licensing and spin-out companies.

What SRI International does

SRI International is an independent, nonprofit research institute founded in 1946 and headquartered at 333 Ravenswood Avenue, Menlo Park, California, with additional Silicon Valley, Princeton (Sarnoff Corporation), San Diego, other U.S. sites, and a Tokyo office. The institute operates five research divisions — Advanced Technology & Systems, Biosciences, Education, Information & Computing Sciences, and Integrated Systems & Solutions — and runs an explicit Commercialization arm comprising Commercial R&D, Ventures, the Center for Innovation Strategy & Policy, and the Nomura-SRI Innovation Center. Its workforce of 1,001–5,000 serves U.S. federal agencies (DARPA, ARPA-H, NASA, NIH, NSF, DOE, IARPA, Army/Marines) and commercial customers across aerospace, pharma, energy, banking, and technology.

SRI's core proprietary technology spans the FOX Three biosensor and molecular-guidance platform (radionuclide therapy and at-home multi-cancer screening via the ARPA-H POSEIDON program, up to $34M awarded in 2025), the BioCyc family of metabolic pathway databases licensed to 11,000+ users, the DASL (Deep Adaptive Semantic Logic) framework for data-efficient AI, the FRASTA 3D fracture-analysis system, the FlexTrain military training instrumentation, the QED-C quantum consortium (270 members), and a deep AI research stack built around the Artificial Intelligence Center (founded 1966), whose outputs include CALO (the progenitor of Siri), RANSAC computer vision, and current agent frameworks (ATHENA, COLLEAGUE). Nine IEEE Milestones and nine Emmy awards attest to a multi-decade innovation record.

SRI's business model rests on multi-year fee-for-service contract R&D with government and industry (e.g., the five-year, $150M DARPA CALO/PAL program), supplemented by licensing of patented inventions and FDA-approved drugs (bexarotene, pralatrexate, vidarabine), subscription licensing of the BioCyc database family, equity realizations from spin-out companies (Siri → Apple, Tempo AI → Salesforce, Summly → Yahoo, Ravenswood Solutions spun out 2024, Autonomique spun out 2026), and consortium management fees (QED-C). Pricing is quote-based and engagement-specific, with no public price list. Distribution is direct enterprise and government sales, augmented by technology licensing to OEMs and the creation of independent spin-out companies that take products to market while SRI retains a partnership stake.

SRI International firmographics

Firmographics
Name
SRI International
Legal name
SRI International
Website
https://sri.com
Company type
Private
Founded year
1946
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
SRI International is an independent nonprofit research institute founded in 1946 and headquartered in Menlo Park, California, conducting multidisciplinary contract R&D for U.S. federal agencies (DARPA, ARPA-H, NASA, NIH, NSF, DOE, IARPA) and commercial customers across biosciences, AI, quantum, security, and space, and commercializing technology through licensing and spin-out companies.
Ownership category
akta.pro rank

Where SRI International is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices6 records

Markets served

SRI International business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Commercial R&D contracts: Fee-for-service and contract research performed for commercial customers (e.g., Merrill Lynch cash management accounts, Valeant/Eisai/Ligand pharmaceutical development, Ricoh digital fax). SRI states it collaborates "closely with government and commercial customers to meet their precise needs and specifications."
  2. Government R&D contracts and grants: Multi-year awards from federal agencies including DARPA (e.g., $150M CALO program, CHERI architecture), ARPA-H (up to $34M for at-home cancer screening), Department of Energy / SETO ($900K in 2017 for PV recycling), NIH, NSF, IARPA, and NASA.
  3. Technology licensing and royalties: Out-licensing of patented inventions and FDA-approved drug royalties. Examples: Ricoh (digital fax Z-60 / RIFAX 600s in 1973), Eisai/Valeant (bexarotene/Targretin for cutaneous T-cell lymphoma, FDA approved 1999), Allos Therapeutics (pralatrexate, FDA approved 2009), Mitsubishi Heavy Industries / Osaka Gas / Chubu Electric (FRASTA), Fourward Technologies (Eyetracker).
  4. Spin-out ventures and equity realizations: Creation of independent companies around SRI technology that the institute may retain a partnership stake in (e.g., Siri → Apple acquisition 2010; Tempo AI → Salesforce; Summly → Yahoo; Meta → Chan-Zuckerberg Initiative; Ravenswood Solutions spun out 2024). The Ventures arm manages these equity positions.
  5. Scientific database subscriptions / licensing: Licensing of the BioCyc / MetaCyc / EcoCyc / HumanCyc family of bioinformatics databases and Pathway Tools software to 11,000+ university and corporate users; supported by NIH funding.
  6. Strategic innovation partnerships: Joint ventures and co-development programs such as the Nomura-SRI Innovation Center, and consulting/coordination contracts like the Flinn Foundation Arizona Bioscience Roadmap engagement.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based contract R&D engagements, not publicly priced.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

SRI International product offering

Product offering

Core offering

SRI International is an independent nonprofit research institute that performs multidisciplinary contract research and development for U.S. government agencies and commercial customers across biosciences, advanced technology and systems, information and computing sciences, and integrated systems and solutions. The institute sells custom R&D services under multi-year contracts and grants, licenses patented inventions and FDA-approved drugs to industry partners, and spins out independent companies to commercialize breakthrough technologies such as Siri, Ravenswood Solutions, and Autonomique.

Product overview

SRI International is a global, independent nonprofit R&D institute (founded 1946) operating as a multi-division research organization rather than a single commercial product. Its Artificial Intelligence Center (founded 1966) anchors a portfolio that includes the FOX Three platform for molecular biosensing and cancer diagnostics, the BioCyc family of bioinformatics databases with Pathway Tools software, and AI agent research products including DASL (Deep Adaptive Semantic Logic), AiCorb generative architecture design, the COLLEAGUE agent framework, and the ATHENA virtual CoP member. Commercialized spinouts and licensed products include Siri (acquired by Apple), Ravenswood Solutions (military training, spun out 2024), Autonomique (teleoperation robotics, spun out 2026), and the FRASTA fracture analysis system. SRI also manages the Quantum Economic Development Consortium (QED-C) and operates the SRI Dish radio antenna for satellite calibrations and spacecraft communications.

Differentiator

Problem solved

Functional benefit

Brands

  • BioCyc: Family of bioinformatics knowledge bases and tools (including MetaCyc, EcoCyc, HumanCyc, and Pathway Tools) developed by SRI's Bioinformatics Research Group; licensed by over 11,000 users to support biological research.
  • Nomura-SRI Innovation Center
  • Sarnoff Corporation

Products and services

  • FOX Three biosensor and molecular guidance platform SRI's molecular guidance system platform enabling rapid, tumor-specific radionuclide delivery. Originally developed for neuroendocrine tumors; extended to pancreatic ductal adenocarcinoma, glioblastoma, and at-home multi-cancer screening through the ARPA-H POSEIDON program.
  • BioCyc database collection (BioCyc, MetaCyc, EcoCyc, HumanCyc) Comprehensive Pathway/Genome Databases for thousands of organisms, including EcoCyc (E. coli), MetaCyc (largest curated metabolic knowledge base), HumanCyc, and BioCyc. Licensed by over 11,000 users at universities and corporate labs worldwide; supported by U.S. NIH funding.
  • Pathway Tools software SRI's bioinformatics software suite supporting metabolic pathway queries, genome browsing via the Genome Explorer browser, multi-omics visualization, and the Comparative Genome Dashboard for cross-organism gene-function comparison.
  • DASL (Deep Adaptive Semantic Logic) Next-generation AI technology that combines state-of-the-art machine learning with reasoning mechanisms to learn from limited data combined with human knowledge, identifying problems and explaining them clearly.
  • FRASTA (Fracture Surface Topography Analysis) 3D fractography system that reconstructs fracture events using confocal optics and scanning laser microscopy to diagnose and predict fatigue failure in pipelines, aircraft, bridges, and power plants. Licensed to NASA and to Japanese companies including Mitsubishi Heavy Industries, Osaka Gas Company, and Chubu Electric Power Company.
  • FlexTrain multi-mission instrumentation system Live, virtual, and constructive training integration system used by the Army National Guard's eXportable Combat Training Capability (XCTC) program to train combat and functional brigades at home stations. Now operated by the Ravenswood Solutions spinout.
  • Quantum Economic Development Consortium (QED-C) Public-private partnership established under the National Quantum Initiative Act of 2018 and managed by SRI International. Coordinates 270 members from government agencies, universities, and private sector companies in quantum technology, workforce, standards, and use cases.
  • SRI contract R&D services for federal and commercial customers Multidisciplinary contract research and development services delivered to U.S. federal agencies and commercial customers across biosciences, advanced technology and systems, information and computing sciences, and integrated systems and solutions. Engagements are multi-year and tailored to specific customer needs.
  • Nomura-SRI Innovation Center Joint innovation center with Nomura supporting Japanese-market partnerships, joint laboratories, co-development, technology transfer, and talent exchange between Silicon Valley and Japan.

Quantifiable outcome

  • Up to $34 million awarded by ARPA-H to develop at-home screening tests capable of detecting 30+ cancer types (2025).
  • +5 more outcomes

Companies that use SRI International

Customer profile

Named customers16 records

Segments5 records

Ideal customer profiles4 records

SRI International technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability16 records

Feature10 records

SRI International partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered flagship, core and minor.

  • Kalekona RadiotheranosticsflagshipStrategic or Co-development Partner · 21 October 2025SRI and Kalekona Radiotheranostics announced a strategic partnership to develop peptide receptor radionuclide therapy (PRRT) for pancreatic ductal adenocarcinoma and glioblastoma, utilizing SRI's FOX Three platform. The platform allows rapid, tumor-specific radionuclide delivery, now extended beyond neuroendocrine tumors to include pancreatic and brain tumors.
  • ARPA-H (Advanced Research Projects Agency for Health)flagshipStrategic or Co-development Partner · 20 October 2025ARPA-H selected SRI's multi-party team — including Foothold Labs, Triple Ring Technologies, and Beacon DX Health — under the POSEIDON program to develop an at-home cancer screening test capable of detecting more than 30 cancer types in early stages. The award is for up to $34 million and leverages SRI's FOX Three biosensor/molecular-guidance platform, AI, and machine learning.
  • Flinn FoundationcoreStrategic or Co-development Partner · 1 September 2025The Flinn Foundation commissioned SRI to deliver an updated Arizona Bioscience Roadmap unveiled in September 2025, highlighting Flagstaff as a leading hub for medical devices, healthcare delivery, precision medicine, and biotechnology.
  • Ravenswood Solutions (spin-out)flagshipStrategic or Co-development Partner · 19 September 2024In September 2024, SRI spun out Ravenswood Solutions as an independent small business focused on fielding scalable, modular solutions for training, testing, and operations across defense and commercial applications. SRI "remains a valuable business partner" to Ravenswood, providing innovative technologies and technical expertise; Ravenswood is headquartered in Fremont, California.
  • Quantum Economic Development Consortium (QED-C)flagshipStrategic or Co-development Partner · 1 January 2018QED-C is a public-private partnership established under the National Quantum Initiative Act of 2018 and managed by SRI International; 270 members from government agencies, universities, and private sector. SRI coordinates investment in quantum technology, workforce, standards, and use cases.
  • DARPA (Defense Advanced Research Projects Agency)flagshipStrategic or Co-development Partner · 1 January 2003Long-term R&D partnership including the five-year, $150M PAL program (CALO cognitive assistant, 22 institutions, 300+ researchers) and ongoing DARPA-funded programs such as CHERI capability-based hardware architecture and Artificial Social Intelligence for Successful Teams (ASIST). Newton's 41-year RISKS Digest was also based at SRI.
  • Allos TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 1 January 2002"Pralatrexate was ultimately identified as a viable clinical candidate and was licensed to Allos Therapeutics for further development in 2002." FDA-approved 2009 for peripheral T-cell lymphoma.
  • Eisai / Ligand / ValeantcoreOEM/ Whitelabel/ Licensing Partner · 1 January 1999"Bexarotene (trade name Targretin) was developed by the San Diego biotech company, Ligand, which subsequently licensed worldwide rights to a Japanese pharmaceutical company, Eisai, in 1999. It is now marketed in the U.S. by the Canadian pharmaceutical company, Valeant, which acquired rights to the drug from Eisai in 2013."
  • Fourward Technologies (now Fourward Optical Technologies)coreOEM/ Whitelabel/ Licensing Partner · 1 January 1988"In 1988, the technology [Eyetracker] was licensed to Fourward Technologies, which continued its development and marketing and installed Eyetrackers all over the world." Developed at SRI under NASA contract from 1965-1988.
  • RicohflagshipOEM/ Whitelabel/ Licensing Partner · 1 April 1973"In 1970, SRI International was contracted by Savin, CBS Television Services and Dacom to commercialize… digital fax. SRI developed the Z-60 prototype. In 1973, Ricoh acquired the rights to the technology; they formed a subsidiary, Rapifax Corporation, to market and distribute the new machine." Ricoh launched the RIFAX 600s, the world's first commercially available digital fax machine.
  • UCLA, USC, BBN, Stanford, Linkabit, Collins Radio (ARPANET founders)flagshipStrategic or Co-development Partner · 29 October 1969Historical consortium that built ARPANET and the first Internet connection. "The very first transmission on the ARPANET occurred at 10:30 p.m. on October 29, 1969, when UCLA attempted to send a message to SRI." Subsequent SRI contributions include internetworking (1977) and the Network Information Center (NIC, 1970-1991).
  • AppleflagshipOEM/ Whitelabel/ Licensing PartnerSRI's CALO project spun out as Siri in 2007; Apple acquired Siri and integrated it into the iPhone 4S in 2011, bringing voice assistants into the mainstream. SRI remains an originator-licensor relationship.
  • SalesforcecoreOEM/ Whitelabel/ Licensing PartnerSRI spin-off Tempo AI was acquired by Salesforce, extending SRI's commercialization lineage.
  • Yahoo / Chan-Zuckerberg InitiativeminorOEM/ Whitelabel/ Licensing PartnerSRI spin-offs Summly was acquired by Yahoo; Meta was acquired by the Chan-Zuckerberg Initiative.
  • Mitsubishi Heavy Industries, Osaka Gas Company, Chubu Electric Power Company, NASAcoreOEM/ Whitelabel/ Licensing PartnerLicensees of SRI's FRASTA fracture-analysis technology for diagnosing and predicting fatigue failure in pipelines, aircraft, bridges, and power plants. NASA and three Japanese companies use FRASTA to analyze 3D fracture surface topography.
  • Nomura-SRI Innovation CenterflagshipStrategic or Co-development PartnerSRI operates the Nomura-SRI Innovation Center as part of its Commercialization division (sri.com/commercialization/the-nomura-sri-innovation-center/), supporting Japanese-market partnerships, joint labs, and technology transfer.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

SRI International competitors and assessment

Company assessment

Peers

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

SRI International social profiles

Digital presence

SRI International compliance and trust

Trust signal

Compliance5 records

SRI International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SRI International leadership team

Management profile

Number of profiles

Profiles11 records

SRI International subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SRI International funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SRI International M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SRI International

What does SRI International do?

SRI International is an independent nonprofit research institute that performs multidisciplinary contract research and development for U.S. government agencies and commercial customers across biosciences, advanced technology and systems, information and computing sciences, and integrated systems and solutions. The institute sells custom R&D services under multi-year contracts and grants, licenses patented inventions and FDA-approved drugs to industry partners, and spins out independent companies to commercialize breakthrough technologies such as Siri, Ravenswood Solutions, and Autonomique.

Is SRI International a public or private company?

SRI International is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was SRI International founded?

SRI International was founded in 1946. It employs 1,001 to 5,000 people.

Where is SRI International based?

SRI International is headquartered in Menlo Park, United States, in the North America region.

How does SRI International make money?

Six revenue lines are on record. Commercial R&D contracts are the primary driver. The others are government R&D contracts and grants, technology licensing and royalties, spin-out ventures and equity realizations, scientific database subscriptions / licensing and strategic innovation partnerships.

Who are SRI International's main competitors?

Peers on record are Battelle Memorial Institute, MITRE Corporation, RAND Corporation, The Aerospace Corporation, Institute for Defense Analyses (IDA), Sandia National Laboratories, Lincoln Laboratory (MIT), Lawrence Livermore National Laboratory, Pacific Northwest National Laboratory (PNNL) and Leidos Holdings.

Does SRI International have an API?

No public API is recorded for SRI International.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NateKorean defense innovation company collaborates with the company that developed iPhone 'Siri' on ultra-small satellite technology: Nate NewsDAPA announced technology cooperation between defense company Step Lab and SRI International, which developed Siri's underlying technology. The collaboration will develop an ultra-small satellite system with an optical payload for space domain awareness, with Step Lab signing a 36-month contract. The project aims to demonstrate space domain awareness performance.The Mercury NewsMenlo Park project at SRI campus adds hundreds of homes, trims office plansLane Partners proposed a revised Parkline plan at the SRI campus in Menlo Park, adding 1,082 homes and cutting office space from 1.38 million to 900,000 square feet. The plan reduces commercial land from 37 to 14 acres and increases residential land from 16 to 44 acres. The proposal would demolish all existing buildings, ending SRI's 75-year presence.Energies MediaAnchored to the seafloor and flying in slow motion, these underwater kites could quietly end diesel dependency in remote coastal communitiesSRI International and Minesto are advancing tidal kite technology to provide predictable clean power for remote coastal communities, aiming to replace diesel generators. SRI's Manta project is currently testing prototypes in San Francisco Bay with a U.S. Department of Energy contract targeting production costs under $0.09 per kilowatt-hour. Meanwhile, Minesto operates a 1.2-megawatt system in the Faroe Islands, and other firms like BladeRunner Energy are trialing devices in Alaska.nj‘Hey, Siri. How do I draw blood?’ New AI medical tech is transforming healthcare. Are we ready?SRI International, in partnership with the Mayo Clinic and the University of Florida, is developing an AI-driven system to guide healthcare workers through clinical procedures like blood draws using smart glasses and computer vision. The project is funded by a $26.5 million award from the Advanced Research Projects Agency for Health (ARPA-H) as part of the five-year PARADIGM program aimed at improving access to medical services in remote areas.SRISRI to relocate Silicon Valley headquarters to its PARC campusSRI will relocate its Silicon Valley headquarters to its Palo Alto-based PARC campus, bringing its teams and labs together. The move coincides with SRI's 80th anniversary and includes refurbishment and modernization. The campus will serve as a hub for startups and international collaborations.EIN PresswireSRI to relocate Silicon Valley headquarters to its PARC campusSRI will relocate its Silicon Valley headquarters to its Palo Alto-based PARC campus, bringing its teams together. The move coincides with SRI's 80th anniversary and will include refurbishment and modernization. The campus will serve as a hub for startups and international collaborations.Tech TimesFirst Quantum Computation of Fusion Fuel Lands as White House Sets 2030 ClockResearchers from Oak Ridge, Cleveland Clinic, and IBM performed the first quantum computation of fusion fuel material FLiBe, modeling nine molecular configurations. The White House set a 2030 deadline for federal contractors to adopt post-quantum cryptography, while agencies must submit migration plans by October 2026.Photonics SpectraNSTDA, VUB, Advance Thailand’s Photonics Capabilities: Week in Brief: 7/3/26This article reports on multiple independent developments in the photonics and quantum sectors, including a $20 million investment by NIST and SRI International to establish a Quantum Manufacturing Engineering Center in the U.S., and CCRAFT closing a $7.8 million funding round to scale thin-film lithium niobate manufacturing in Switzerland. Other key events include MKS expanding its Guangzhou facility with a $25 million investment, the Berkshire Innovation Center receiving state awards for optics manufacturing, and various partnerships involving Fraunhofer ILT, LEOS, MPB Communications, and SuperX AI Technology.Quantum Computing ReportNIST and SRI International Partner to Launch $20 Million Quantum Manufacturing Engineering CenterNIST and SRI International have launched the Quantum Manufacturing Engineering Center (QMEC) with an initial $20 million investment to bridge the gap between laboratory quantum research and commercial-scale manufacturing. The center will focus on two critical infrastructure pillars: standardizing industrial cryostats and dilution refrigerators for maintaining quantum computing thermal conditions, and driving volume manufacturing of precision laser assemblies for qubit manipulation. This initiative directly implements federal mandates from the Executive Order on Quantum Innovation and builds on the prior Quantum Economic Development Consortium established under the National Quantum Initiative Act.EIN PresswireNIST taps SRI to establish the Quantum Manufacturing Engineering CenterNIST and SRI announced the Quantum Manufacturing Engineering Center (QMEC) to accelerate quantum technology manufacturing. Initial focus areas include cryostats and lasers, with a goal to advance manufacturability within three years. The center will recruit quantum experts and companies to strengthen supply chains.